Advertisement

Topics

DeuteRx, LLC Company Profile

21:01 EDT 23rd June 2018 | BioPortfolio

DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications. The development of the single, preferred enantiomer from the parent racemic drug, also known as a 'chiral switch', often leads to drugs with superior therapeutic properties. However, numerous drugs are still developed and marketed as racemic mixtures because their enantiomers chemically interconvert in vivo. To date, DeuteRx has demonstrated the use of DECS to stabilize and characterize the enantiomers of many racemic active ingredients. DRX-065, deuterium-stabilized R-pioglitazone, is in Phase 1 at DeuteRx and is being pursued for NASH and adrenomyeloneuropathy (AMN), a rare monogenic neurological disease. DeuteRx’s second program, DRX-164, is a DECS of avadomide (CC-122). Avadomide is a racemic cereblon E3 ligase modulator (CELMoD®) currently in development at Celgene for hematological malignancies and solid tumors. DeuteRx published preclinical results demonstrating that the anti-inflammatory and anti-tumorigenic effects of avadomide are due exclusively to the S-enantiomer (Jacques, et al., PNAS 2015, 24, 112(12), E1471-1479).


News Articles [1 Associated News Articles listed on BioPortfolio]

DeuteRx to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference

Presentation to be webcast on March 19 at 5:20 p.m. ET DeuteRx LLC, a clinical stage biopharmaceutical company dedicated to improving racemic drugs, today announced tha...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

DeuteRx LLC

DeuteRx is pioneering ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) s...

DeuteRx, LLC

DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a mixture of two mirror-image compounds or enantiomers) s...

DeuteRx

More Information about "DeuteRx, LLC" on BioPortfolio

We have published hundreds of DeuteRx, LLC news stories on BioPortfolio along with dozens of DeuteRx, LLC Clinical Trials and PubMed Articles about DeuteRx, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of DeuteRx, LLC Companies in our database. You can also find out about relevant DeuteRx, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record